Rallybio (NASDAQ:RLYB – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.26), FiscalAI reports. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.23 million.
Rallybio Stock Performance
RLYB stock traded up $0.32 during trading on Wednesday, hitting $14.35. The company had a trading volume of 150,607 shares, compared to its average volume of 633,223. The business has a 50 day moving average of $9.63 and a 200 day moving average of $6.86. Rallybio has a fifty-two week low of $2.16 and a fifty-two week high of $15.31.
Insiders Place Their Bets
In related news, major shareholder Adar1 Capital Management, Llc acquired 35,101 shares of Rallybio stock in a transaction that occurred on Tuesday, May 5th. The stock was acquired at an average price of $14.00 per share, with a total value of $491,414.00. Following the completion of the acquisition, the insider directly owned 779,784 shares of the company’s stock, valued at $10,916,976. This trade represents a 4.71% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.30% of the stock is owned by insiders.
Institutional Investors Weigh In On Rallybio
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on RLYB. Weiss Ratings reissued a “sell (d-)” rating on shares of Rallybio in a report on Friday, May 8th. Wall Street Zen raised shares of Rallybio to a “hold” rating in a report on Saturday, March 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.
View Our Latest Stock Report on Rallybio
Rallybio Company Profile
Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.
Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.
Read More
- Five stocks we like better than Rallybio
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
